Clinical Laboratory Improvement Advisory Committee (CLIAC), 1063 [2010-100]

Download as PDF Federal Register / Vol. 75, No. 5 / Friday, January 8, 2010 / Notices opportunity announcements; (2) conduct of Secondary Peer Review of extramural research grants, cooperative agreements, and contracts applications received in response to the funding opportunity announcements as it relates to the Center’s programmatic balance and mission; (3) submission of secondary review recommendations to the Center Director of applications to be considered for funding support; (4) review of research portfolios; and (5) review of program proposals. The board shall provide guidance on the National Center of Injury Prevention and Control’s programs and research activities by conducting scientific peer review of intramural research and programs within the National Center for Injury Prevention and Control; by ensuring adherence to Office of Management and Budget requirements for intramural peer review; and by monitoring the overall direction, focus, and success of the National Center for Injury Prevention and Control. Matters to be Discussed: As this meeting of the Board of Scientific Counselors, the board will be discussing the upcoming portfolio topics, activities promoting the Injury Research Agenda, and other scientific matters. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Dr. Gwendolyn Cattledge, PhD, MSEH, Deputy Associate Director for Science and the Designated Federal Officer for the Board of Scientific Counselors, NCIPC, CDC, 4770 Buford Highway, NE., Mailstop F–63, Atlanta, Georgia 30341, Telephone (770) 488–1430. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2010–22 Filed 1–7–10; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention pwalker on DSK8KYBLC1PROD with NOTICES Clinical Laboratory Improvement Advisory Committee (CLIAC) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting: Times and Dates: 8:30 a.m.–5 p.m., February 9, 2010. 8:30 a.m.–3 p.m., February 10, 2010. Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global Communications VerDate Nov<24>2008 16:14 Jan 07, 2010 Jkt 220001 Center, Building 19, Room 232, Auditorium B, Atlanta, Georgia 30333. Online Registration Required: In order to expedite the security clearance process at the CDC Roybal Campus located on Clifton Road, all CLIAC attendees are required to register for the meeting online at least 14 days in advance at http://wwwn.cdc.gov/cliac/ default.aspx by clicking the ‘‘Register for a Meeting’’ link and completing all forms according to the instructions given. Please complete all the required fields before submitting your registration and submit no later than January 26, 2010. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people. Purpose: This Committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances. Matters To Be Discussed: The agenda will include updates from the CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration; a report from the CLIAC Biochemical Genetic Testing Workgroup and discussion of the Workgroup’s proposals related to good laboratory practices for biochemical genetic testing; and presentations and discussions related to electronic health records and electronic transmission of laboratory information. Agenda items are subject to change as priorities dictate. Providing Oral or Written Comments: It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. Oral Comments: In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting’s Summary Report. To assure adequate time is scheduled for public comments, individuals or groups planning to make an oral presentation should, when possible, notify the contact person below at least one week prior to the meeting date. Written Comments: For individuals or groups unable to attend the meeting, PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 1063 CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments, one hard copy with original signature, should be provided to the contact person below. Written comments will be included in the meeting’s Summary Report. Contact Person for Additional Information: Nancy Anderson, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, National Center for Preparedness, Detection, and Control of Infectious Diseases, CDC, 1600 Clifton Road, NE., Mailstop F–11, Atlanta, Georgia 30333; telephone (404) 498–2741; fax (404) 498–2219; or via e-mail at Nancy.Anderson@cdc.hhs.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for CDC and the Agency for Toxic Substances and Disease Registry. Dated: December 30, 2009. Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2010–100 Filed 1–7–10; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. E:\FR\FM\08JAN1.SGM 08JAN1

Agencies

[Federal Register Volume 75, Number 5 (Friday, January 8, 2010)]
[Notices]
[Page 1063]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-100]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:
    Times and Dates:

8:30 a.m.-5 p.m., February 9, 2010.
8:30 a.m.-3 p.m., February 10, 2010.
    Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global 
Communications Center, Building 19, Room 232, Auditorium B, Atlanta, 
Georgia 30333.
    Online Registration Required: In order to expedite the security 
clearance process at the CDC Roybal Campus located on Clifton Road, all 
CLIAC attendees are required to register for the meeting online at 
least 14 days in advance at http://wwwn.cdc.gov/cliac/default.aspx by 
clicking the ``Register for a Meeting'' link and completing all forms 
according to the instructions given. Please complete all the required 
fields before submitting your registration and submit no later than 
January 26, 2010.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the standards 
under which clinical laboratories are regulated; the impact on medical 
and laboratory practice of proposed revisions to the standards; and the 
modification of the standards to accommodate technological advances.
    Matters To Be Discussed: The agenda will include updates from the 
CDC, the Centers for Medicare & Medicaid Services, and the Food and 
Drug Administration; a report from the CLIAC Biochemical Genetic 
Testing Workgroup and discussion of the Workgroup's proposals related 
to good laboratory practices for biochemical genetic testing; and 
presentations and discussions related to electronic health records and 
electronic transmission of laboratory information.
    Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible.
    Oral Comments: In general, each individual or group requesting to 
make an oral presentation will be limited to a total time of five 
minutes (unless otherwise indicated). Speakers must also submit their 
comments in writing for inclusion in the meeting's Summary Report. To 
assure adequate time is scheduled for public comments, individuals or 
groups planning to make an oral presentation should, when possible, 
notify the contact person below at least one week prior to the meeting 
date.
    Written Comments: For individuals or groups unable to attend the 
meeting, CLIAC accepts written comments until the date of the meeting 
(unless otherwise stated). However, the comments should be received at 
least one week prior to the meeting date so that the comments may be 
made available to the Committee for their consideration and public 
distribution. Written comments, one hard copy with original signature, 
should be provided to the contact person below. Written comments will 
be included in the meeting's Summary Report.
    Contact Person for Additional Information: Nancy Anderson, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Systems, 
National Center for Preparedness, Detection, and Control of Infectious 
Diseases, CDC, 1600 Clifton Road, NE., Mailstop F-11, Atlanta, Georgia 
30333; telephone (404) 498-2741; fax (404) 498-2219; or via e-mail at 
Nancy.Anderson@cdc.hhs.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: December 30, 2009.
Gary J. Johnson,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 2010-100 Filed 1-7-10; 8:45 am]
BILLING CODE 4163-18-P